February 23, 2023
Erica Sparkenbaugh, PhD, Rafal Pawlinski, PhD Published in Blood
Sickle cell disease carries a significant risk of venous thrombosis, yet evidence suggests that anti-coagulant therapy increases the risk of bleeding in individuals with SCD. Coagulation FXII, which contributes to thrombosis but not hemostasis, is an appealing target for treating thrombosis without carrying a bleeding risk. Work led by Erica Sparkenbaugh and Rafal Pawlinski demonstrates …